<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ancillary tests in thymic epithelial tumors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ancillary tests in thymic epithelial tumors</h1>
<div class="graphic"><div class="figure"><div class="ttl">Ancillary tests in thymic epithelial tumors</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1" colspan="3">Thymoma</td> </tr> <tr> <td class="subtitle2_left">Cellular component</td> <td class="subtitle2_left">Expressed</td> <td class="subtitle2_left">Negative</td> </tr> <tr> <td>Neoplastic epithelial cells</td> <td> <ul> <li>Keratin AE1/AE3, CAM 5.2, CK5/6, p40, p63</li> <li>PAX8 (100% type A, 93% type B thymomas using polyclonal antibody<sup>[1,2]</sup>)</li> <li>CD20 (some type A, AB)</li> <li>Bcl-2 +/–</li> <li>TTF-1 (rare type A)<sup>[2]</sup></li> </ul> </td> <td> <ul> <li>CK20</li> </ul> </td> </tr> <tr> <td>Thymocytes</td> <td> <ul> <li>TdT (may be absent in type A and B3 thymoma)</li> </ul> </td> <td> </td> </tr> <tr> <td class="subtitle1" colspan="3">Thymic carcinoma</td> </tr> <tr> <td class="subtitle2_left">Carcinoma subtype</td> <td class="subtitle2_left">Expressed</td> <td class="subtitle2_left">Negative</td> </tr> <tr> <td>Squamous cell carcinoma</td> <td> <ul> <li>p40, p63, CK5/6</li> <li>CD5 +/–</li> <li>CD117 +/–</li> <li>PAX-8 (polyclonal)</li> </ul> </td> <td> <ul> <li>CK20</li> </ul> </td> </tr> <tr> <td>NUT carcinoma</td> <td> <ul> <li>NUT</li> <li>p40, CK5/6 +/–</li> <li>TTF-1, CD34 +/–</li> <li>t[15;19] <em>BRD4-NUT</em> translocation; other translocations or fusions involving the <em>NUT</em> locus can occur</li> <li>Simple karyotype</li> </ul> </td> <td> </td> </tr> <tr> <td>Low-grade papillary adenocarcinoma<sup>[3]</sup></td> <td> <ul> <li>CK7</li> <li>CK8</li> <li>EMA+</li> <li>BerEP4+</li> <li>CD5 +/–</li> <li>CEA +/–</li> <li>CD117 +/–</li> </ul> </td> <td> <ul> <li>CK20</li> <li>CDX2</li> <li>Thyroglobulin</li> <li>Calcitonin</li> <li>TTF-1</li> <li>PAX8</li> </ul> </td> </tr> <tr> <td>Mucoepidermoid carcinoma<sup>[4]</sup></td> <td> <ul> <li><em>MAML2</em> rearrangement</li> </ul> </td> <td> </td> </tr> <tr> <td>Enteric-type adenocarcinoma<sup>[3]</sup></td> <td> <ul> <li>CK20</li> <li>CDX2</li> <li>MUC2</li> <li>CK7 +/–</li> <li>CD5 +/–</li> </ul> </td> <td> <ul> <li>TTF-1</li> <li>CD117</li> </ul> </td> </tr> <tr> <td>Adenocarcinoma, NOS<sup>[3]</sup></td> <td> <ul> <li>Pancytokeratin</li> <li>CD5 +/–</li> <li>CEA +/–</li> <li>CA19-9 +/–</li> <li>CK7 +/–</li> </ul> </td> <td> <ul> <li>CK20</li> <li>CDX2</li> <li>MUC2</li> </ul> </td> </tr> <tr> <td class="subtitle1" colspan="3">Immunostains aiding in the distinction between thymic carcinoma and metastases<sup>[2,5]</sup></td> </tr> <tr> <td class="subtitle2_left">Immunostain; % positive cases</td> <td class="subtitle2_left">Thymic carcinoma</td> <td class="subtitle2_left">Metastases</td> </tr> <tr> <td>CD5</td> <td>20 to 100</td> <td>0 to 34*</td> </tr> <tr> <td>CD117</td> <td>60 to 87</td> <td>20 to 100<sup>¶</sup></td> </tr> <tr> <td>CD5 &amp; CD117</td> <td>54 to 65</td> <td>0<sup>Δ</sup></td> </tr> <tr> <td>CD205</td> <td>52 to 76</td> <td>4 to 27</td> </tr> <tr> <td>FoxN1</td> <td>59</td> <td>13</td> </tr> <tr> <td>PAX8</td> <td>0 to 80<sup>◊</sup></td> <td>0 to 33<sup>Δ</sup><sup>◊</sup></td> </tr> <tr> <td>PAX8 &amp; CD117</td> <td>69</td> <td>0</td> </tr> <tr> <td>PAX8 &amp; CD5</td> <td>46</td> <td>0</td> </tr> </tbody></table></div><div class="graphic_footnotes">CAM: cell adhesion molecule; CK: creatine kinase; PAX8: paired box 8; CD: cluster of differentiation; Bcl: B-cell lymphoma; TTF-1: transcription termination factor 1; TdT: terminal deoxynucleotidyl transferase; BRD4: bromodomain-containing 4; NUT: nuclear protein of the testis; MAML2: mastermind-like transcriptional coactivator 2; FoxN1: forkhead box N1; SP19: chymotrypsin-like serine protease.<br/>* Adenocarcinoma of gastrointestinal tract, breast, lung, gynecologic organs, epithelioid sarcoma, mesothelioma, urothelial carcinoma; <strong>clone dependent</strong>.<br/>¶ Squamous cell carcinoma of lung, gastrointestinal stromal tumor, germ cell tumors.<br/>Δ Squamous cell carcinomas of lung (clone SP19, clone not provided in other study).<sup>[6,7]</sup><br/><font class="lozenge">◊</font> Clone-dependent (0 for monoclonal PAX8, 58 to 69% [thymic carcinoma] and 2.4 to 6% [lung carcinomas] for polyclonal PAX8).<sup>[2]</sup></div><div class="graphic_reference">References: 

<ol>
<li>Weissferdt A, Moran CA. Pax8 expression in thymic epithelial neoplasms: An immunohistochemical analysis. Am J Surg Pathol 2011; 35:1305.</li>
<li>Asirvatham JR, Esposito MJ, Bhuiya TA. Role of PAX-8, CD5, and CD117 in distinguishing thymic carcinoma from poorly differentiated lung carcinoma. Appl Immunohistochem Mol Morphol 2014; 22:372.</li>
<li>WHO Classification of Tumours Editorial Board. Thoracic tumours. In: WHO Classification of Tumours, 5th ed, International Agency for Research on Cancer, Lyon, France 2021. Available online at <a href="https://tumourclassification.iarc.who.int/chapters/35" target="_blank">tumourclassification.iarc.who.int/chapters/35</a>.</li>
<li>Roden AC, Erickson-Johnson MR, Yi ES, Garcia JJ. Analysis of MAML2 rearrangement in mucoepidermoid carcinoma of the thymus. Hum Pathol 2013; 44:2799.</li>
<li>Kwon AY, Han J, Chu J, et al. Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature. Pathol Res Pract 2017; 213:106.</li>
<li>Jha V, Sharma P, Mandal AK. Utility of cluster of differentiation 5 and cluster of differentiation 117 immunoprofile in distinguishing thymic carcinoma from pulmonary squamous cell carcinoma: A study on 1800 non-small cell lung cancer cases. Indian J Med Paediatr Oncol 2017; 38:430.</li>
<li>Kriegsmann M, Muley T, Harms A, et al. Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases. Diagn Pathol 2015; 10:210.</li></ol></div><div id="graphicVersion">Graphic 121031 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
